When and Where
Print your Invitation
Travelling / Transportation Info
Mark Your Calendar
Speakers / Posters Registration (Abstracts Submission)
Submit a Workshop
Become a Sponsor / Partner
Join MEMBS Committee
This page will be available by 1 August 2018
This page will be available by 1st October 2018
Prof. Magid Abou-Gharbia
Associate Dean for Research, Laura H. Carnell Professor of Medicinal Chemistry and Director
Moulder Center for Drug Discovery Research
Temple University School of Pharmacy
Magid Abou-Gharbia, Ph.D., FRSC is currently the Associate Dean for Research, Laura H. Carnell Professor of Medicinal Chemistry and Director of the Moulder Center for Drug Discovery Research (MCDDR) at the School of Pharmacy, Temple University, Philadelphia, PA. He is responsible for Setting and implementing School of Pharmacy research strategies to promote the school’s research and entrepreneurial enterprise. Prior to joining Temple University in 2008, Magid spent 26 years at Wyeth Pharmaceuticals where he was Senior Vice President Discovery Research. As Senior Vice President & Head of Chemical & Screening Sciences at Wyeth, he was responsible for overseeing and directing Wyeth chemistry and screening research efforts of 500 scientists at four US research facilities and 150 chemists in Hyderabad, India in support of drug discovery in Neuroscience, Inflammation, Women's Health/Bone, Oncology and Cardiovascular/Metabolic Diseases therapeutic areas. Abou-Gharbia led research efforts that resulted in the discovery of 9 marketed drugs. Abou-Gharbia is credited with >125 US patents, over 350 worldwide Patents, 220 publications, invited lectures and presentations.
Dr. Abou-Gharbia has also been instrumental in establishing and promoting biomedical research in the Middle East. Among his recent contributions are the establishment of Qatar Biomedical Research Institute (QBRRI), instituting medicinal chemistry and drug discovery research at four major educational institution in the region (the University of Sharja’s School of Pharmacy in the UAE, the Misr University for Science and Technology (MUST) in Egypt, Future University in Egypt (FUE) and City of Scientific Research and Technological Applications (SERTA-City) in Egypt). In addition, he continue to welcome and host visiting scholars, faculty, and students in sabbaticals, internships, and fellowships in his laboratories in an effort to further boost biomedical research in the region through training in modern drug discovery methods. Finally, Dr. Abou-Gharbia spearheaded efforts to establish training programs in the Middle East that focus on the regulatory aspects of the drug approval process. Through these programs, students, scientists, and scholars learn the policies and regulation required for drug approval at the FDA and other global regulatory bodies that control the marketing of novel therapies. This training will further facilitate the development of novel therapies through Middle Eastern based research programs.
He serves on the Scientific Advisory Board of several companies and professional societies and has adjunct professor appointments at several universities in the US and abroad. He received numerous awards and honors including two ACS Heroes of Chemistry awards in 2008 for discovery of Torisel and 2014 for discovery of Effexor and was named in 2014 "Researcher and Educator of the Year" by the Philadelphia Business Journal and the PA Bio and Grand Hamdan International Award in the Field of Medical Sciences in Drug Discovery in 2014.